image: Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting evaluating the efficacy and safety of cutaquig® (Immune Globulin Subcutaneous ...
PARAMUS, N.J. (May 18, 2023) – An Octapharma-sponsored study published recently in The Journal of Clinical Immunology concludes that cutaquig ® (Immune Globulin Subcutaneous [Human]-hipp, 16.5% ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency ...
According to FDA, the syringe pumps can cause "serious clinical consequences from lack of flow continuity resulting in delay of therapy, over-infusion or under-infusion," when operating at a rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results